SEC Form SC 13G/A filed by Compass Therapeutics Inc. (Amendment)

2/9/23 8:14:52 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $CMPX alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.3 COMPASS THERAPEUTICS INC COMMON STOCK Cusip #20454B104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #20454B104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 6,354,814 Item 6: 0 Item 7: 6,354,814 Item 8: 0 Item 9: 6,354,814 Item 11: 5.035% Item 12: HC Cusip #20454B104 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 6,354,814 Item 8: 0 Item 9: 6,354,814 Item 11: 5.035% Item 12: IN Item 1(a). Name of Issuer: COMPASS THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 80 GUEST STREET BOSTON, MA 02135 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 20454B104 Item 3. Not Applicable Item 4. Ownership (a) Amount Beneficially Owned: 6,354,814 (b) Percent of Class: 5.035% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 6,354,814 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of COMPASS THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of COMPASS THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing orinfluencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 9, 2023 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA IMPRESA MANAGEMENT LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 9, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of COMPASS THERAPEUTICS INC at December 30, 2022. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January, 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $CMPX alert in real time by email

Recent Analyst Ratings for

$CMPX

Date	Price Target	Rating	Analyst
4/2/2025	$6.00	Market Perform → Outperform	Leerink Partners
2/24/2025	$12.00	Buy	Guggenheim
2/19/2025	$12.00	Overweight	Piper Sandler
12/23/2024	$32.00	Buy	D. Boral Capital
11/15/2024	$5.00 → $4.00	Outperform → Market Perform	Leerink Partners
9/16/2024	$5.00	Neutral → Buy	Ladenburg Thalmann
1/31/2023	$8.00	Buy	Jefferies
1/27/2023	$9.00	Buy	Stifel

More analyst ratings

SEC Form SC 13G/A filed by Compass Therapeutics Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $CMPX

$CMPX Press Releases

Fastest customizable press release news feed in the world

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

Compass Therapeutics to Participate in Upcoming May Investor Events

$CMPX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CHIEF EXECUTIVE OFFICER Schuetz Thomas J. bought $21,100 worth of shares (10,000 units at $2.11), increasing direct ownership by 0.15% to 6,480,825 units (SEC Form 4)

Director Gordon Carl L sold $5,678,571 worth of shares (3,571,428 units at $1.59) (SEC Form 4)

Director Orbimed Advisors Llc sold $5,678,571 worth of shares (3,571,428 units at $1.59) (SEC Form 4)

$CMPX Leadership Updates

Live Leadership Updates

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

Compass Therapeutics Announces CEO Transition

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

$CMPX Financials

Live finance-specific insights

Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009

OTC Markets Group Announces Quarterly Index Performance and Rebalancing

$CMPX SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Compass Therapeutics Inc.

SEC Form 10-Q filed by Compass Therapeutics Inc.

Compass Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$CMPX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Compass Therapeutics upgraded by Leerink Partners with a new price target

Guggenheim initiated coverage on Compass Therapeutics with a new price target

Piper Sandler initiated coverage on Compass Therapeutics with a new price target

$CMPX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CHIEF EXECUTIVE OFFICER Schuetz Thomas J. bought $21,100 worth of shares (10,000 units at $2.11), increasing direct ownership by 0.15% to 6,480,825 units (SEC Form 4)

Gen Counsel & Corporate Sec Anderman Jonathan bought $30,800 worth of shares (20,000 units at $1.54), increasing direct ownership by 2,000% to 21,000 units (SEC Form 4)

CHIEF ACCOUNTING OFFICER Lerner Neil bought $28,400 worth of shares (20,000 units at $1.42), increasing direct ownership by 7% to 320,000 units (SEC Form 4)

$CMPX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Compass Therapeutics Inc.

SEC Form SC 13G filed by Compass Therapeutics Inc.

SEC Form SC 13D/A filed by Compass Therapeutics Inc. (Amendment)

Recent Analyst Ratings for
$CMPX

$CMPX
Press Releases

$CMPX
Insider Trading

$CMPX
Leadership Updates

$CMPX
Financials

$CMPX
SEC Filings

$CMPX
Analyst Ratings

$CMPX
Insider Purchases

$CMPX
Large Ownership Changes